R ecovery from dementia is the key clinical benefit to the patients of Alzheimer's disease (AD). This has become evident after consecutive failures in clinical trials for disease-modifying drugs that target neuropathological hallmarks. Accordingly, the US Food and Drug Administration loosened the standard for AD drug approval 1 . Their new guidance suggests accelerated regulatory pathways for drugs that improve cognitive deficits alone in early stages of AD. Albeit flexible in mechanisms of action, these symptomatic drugs must be assessed in early-stage AD patients with overt dementia and apparent biomarkers, such as amyloid plaques and tau tangles. The next generation acetylcholinesterase inhibitors may well fit into the accelerated pathways. However, the unnecessary stimulation of the normal cholinergic systems in the brains of AD patients and, even, non-demented subjects remains to be solved 2 . Taurine, 2-aminoethanesulfonic acid, is the second most abundant endogenous amino acid in the central nervous system (CNS) and plays multiple roles in our body: thermoregulation, stabilization of protein folding, anti-inflammatory effects, antioxidation, osmoregulation, calcium homeostasis and CNS development [3] [4] [5] [6] [7] [8] [9] ( Figure 1 ). Due to its nontoxic and curative properties, taurine is frequently found in food, drinks and drugs for treating liver and heart disorders [10] [11] [12] [13] . Recently, taurine has shown therapeutic effects as a cognitive enhancer in animal models of non-AD neurological disorders. Taurine recovers memory impairments of mice induced by alcohol, pentobarbital, sodium nitrite and cycloheximide without any observable effects on other behaviours including motor coordination, exploratory activity and locomotor activity 14 . Cognitive deficits of rats from excess manganese exposure are improved, and upregulated acetylcholinesterase activity is partially restored after taurine administration 15 . The intracerebroventricular administration of taurine protects mice from hypoxia-induced learning impairment 16 . In addition, intravenously administered taurine significantly improves post-injury functional impairments of traumatic brain injury in rats 17 . Taurine supplementation has also been found to rescue ageing-dependent loss of visual discrimination in mice 18 . In streptozotocin-induced sporadic dementia rat models, cognitive impairment and abnormal acetylcholinesterase activity is ameliorated by taurine 19 . Notably, taurine does not enhance learning and memory in cognitively intact adult rodents 20 .
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Taurine also has multiple disease-modifying roles to prevent or cease neuropathology of AD. During the development of AD, amyloid-b (Ab) progressively misfolds into toxic aggregates, which are strongly associated with neuronal loss, synaptic damages and brain atrophy. The electron microscopy study indicates that taurine weakly inhibits Ab aggregation 21 . Anti-inflammatory and anti-oxidant properties of taurine also protect neuronal cells and mitochondria from neurotoxicity of Ab. By activating GABA and glycine receptors, taurine inhibits excitotoxicity caused by Ab-induced glutamatergic transmission activation 22 . Taurine is also observed to attenuate Abassociated neuronal cell death, mitochondrial permeability transition pore opening, mitochondrial dysfunction and intracellular reactive oxygen species generation by activating Sirtuin 1 [23] [24] [25] [26] . Therapeutic effects of taurine remain to be investigated in demented animal models with AD pathology. Considering the reevaluation of anti-amyloidogenic homotaurine for the potential role to ameliorate the cholinergic transmission in early AD, its analog compounds such as taurine are valuable therapeutic candidates for both cognitive enhancement and disease-modification (Figure 1 ) 27 . In this study, we examined both symptomatic and diseasemodifying effects of taurine in the demented adult APP/PS1 transgenic AD mouse model. Taurine was orally administered to the mice via drinking water for 6 weeks. The Y-maze and the passive avoidance tasks were then performed in succession to test for improvement of the spatial working memory and the contextual learning abilities, respectively. After sacrificing the animals for their cerebrospinal fluid (CSF) and brains, we measured alterations of Ab levels in soluble, insoluble and plaque forms by sandwich enzymelinked immunosorbent assays (ELISA) and Ab burden assay (ThS staining). In addition, we measured the level of reactive astrocytes by immunohistochemistry (IHC) and western blots.
Results
Animal model and oral administration of taurine. To examine therapeutic efficacy of orally administered taurine as a cognitive enhancer in the early dementing stage of AD, we utilized APPswe/ PS1-dE9 transgenic mouse model at the age of 7 months and dissolved taurine in the drinking water for 6-week administration. This mouse model produces elevated amount of human Ab peptides by expressing mutant human amyloid precursor protein (APP) and presenilin protein 1 (PS1) 28 . This model is reported to express abnormal learning and memory behaviours with Ab/tau alterations as early as the age of 6 months 29, 30 . The 7-month old APP/PS1 mice (n 5 19, male) and their age-matched wild-type littermates (n 5 20, male) were divided into groups depending on presence of taurine in the drinking water. To orally administer 1,000 mg/kg/day of taurine to the mice, amounts of taurine in each water container was calculated based on daily water consumption and weekly check-up on body weights. Oral dosage of 1,000 mg/kg/day to mice was justified based on previously reported taurine in vivo studies and the median lethal dose (over 7,000 mg/kg) [14] [15] [16] [17] [18] [19] [20] . Throughout the experiment we did not observe any changes in hair loss, water consumption or body weight.
Taurine improves spatial working memory in APP/PS1 mice in the Y-maze task. To assess the spatial working memory of APP/PS1 mice, we performed the Y-maze test at the end of 6-week taurine administration. In the 3-armed Y-shaped maze, a mouse is free to explore, and the sequence of entries is recorded to determine the number of visits to 3 different arms in a row. The analyzed percent alternation reflects the function of visual cortex function of the subjected mouse, and higher percent alternation indicates better spatial memory. In this study, we found that taurine supplementation significantly improved behavioural performance of the APP/PS1 mice on the Y-maze test as compared to the wateronly APP/PS1 group (Figure 2A) . The spatial working memory of APP/PS1 mice was recovered up to wild-type levels ( Figure 2A ). We found insignificant changes among the total number of arm entries, dismissing hyperactivity as a possible argument for cognitive improvement (Figure 2A ).
Taurine improves hippocampal memory in APP/PS1 mice in the passive avoidance task. To evaluate the hippocampal memory of APP/PS1 mice, we performed the passive avoidance test 2 days after the Y-maze test. The passive avoidance test is a fear-motivated test to assess the function of hippocampus and amygdala of the subject. The test requires rodents to resist their affinity for the darker chamber and remain in the lighter chamber of a 2-chamber box. In the acquisition phase, a mouse is placed inside the bright chamber and receives a shock when it traverses to the dark side. After 24 hrs, the mouse is again placed in the bright chamber of the box, and how well it remembers the shock is measured by the latency in avoiding the dark chamber. Higher latency value translates to better retention of memory from the foot-shock given during the learning phase. Consistent with the results obtained from the Y-maze, taurine was observed to significantly enhance behavioural performance of the APP/PS1 mice in the pass avoidance tasks as compared to the nontreated APP/PS1 group ( Figure 2B ). The hippocampal memory of the taurine-treated APP/PS1 mice was recovered to the level similar to that of wild-type mice ( Figure 2B ). Similar to the results from the Ymaze test, behavioural alterations of the wild-type by taurine treatment was insignificant ( Figure 2B ).
Taurine decreases insoluble Ab 42 in the cortex of APP/PS1 mice. Ab accumulation in the brain reflects the onset of AD 31 . As taurine was reported to bind Ab peptides with weak anti-fibrillogenic effect, we measured alterations of plaque, soluble and insoluble forms of Ab 21, 32 . To examine the effect of orally administered taurine on the alteration of plaque burden, brains of APP/PS1 mice were sectioned after behavioural tests, and then stained with thioflavin S (ThS). ThS was used to visualize b-sheet-rich Ab plaques. In comparison to the non-treated APP/PS1 group, no significant difference was found in numbers, area or average size of plaques in taurine-treated APP/PS1 group (Figure 3) . Consistent with the results from ThS staining, we did not observe alterations in levels of plaques and amyloid precursor protein by IHC using the monoclonal anti-Ab antibody, 6E10 ( Figure 4A and 4B). Among various isomers of Ab, Ab 42 is the most amyloidogenic and neurotoxic. In order to determine whether Ab 42 peptides were involved in amelioration of cognitive deficits in APP/PS1 mice, we prepared brain lysates of animals subjected to aforementioned behavioural studies and isolated soluble and insoluble Ab fractions of both the hippocampus and the cortex for sandwich-ELISA. In the hippocampal region, levels of soluble and insoluble Ab 42 were not altered by taurine administration ( Figure 4C ). In addition, we did not observe changes in soluble Ab 42 levels in the cortices of APP/PS1 mice by taurine treatment. On the contrary, we found a significant decrease in the level of Ab 42 in the cortical insoluble fraction of the taurinetreated APP/PS1 mice as compared to the non-treated APP/PS1 group ( Figure 4C ). CSF Ab 42 and tau levels are associated with neuropathological changes in AD brains 33 . In comparison between 2 transgenic groups, we did not observe differences in CSF Ab 42 ( Figure 4D ) or tau levels (data not shown). Collectively, these results indicate that 6-week oral administration of taurine (1,000 mg/kg/day) only reduced levels of Ab 42 insoluble fractions of the cortex.
Taurine treatment increases levels of reactive astrocytes in the hippocampus and the cortex. Reactive astrocytes are found in various CNS disease brains to limit inflammation and to protect neurons from tissue degeneration 34 . In AD, reactive astrocytes cluster around Ab plaques as a glial response to the neural injury associated with Ab 35 . Therefore, we measured glial fibrillary acidic protein (GFAP), a marker for astrocytosis, in the brains of taurinetreated mice by IHC and western blots. In IHC analyses, reactive astrocytes were colocalized with both ThS-and 6E10-stained plaques in transgenic mouse brains ( Figure 4A and 4B) . To quantify levels of GFAP expression, we performed western blot analyses. Interestingly, we found that oral administration of taurine induced increase of reactive astrocytes in both the wild-type and transgenic mice ( Figure 4E ). Because taurine treatment selectively enhanced behavioural performance of APP/PS1 groups in Y-maze and passive avoidance tasks without affecting wild-type mice, it is difficult to correlate the increase of astrocytosis with learning and memory in this study.
Discussion
Here we report that taurine in drinking water rescues Alzheimer-like learning and memory deficits of adult APP/PS1 double transgenic mice without modifying the behaviours of cognitively normal mice. Our current study complements a previous study that reported the ability of taurine to improve learning and retention in aged FVB/NJ mouse model compared to their untreated controls 36 . Unlike APP/ PS1 mouse model, which expresses human Ab and amyloidogenesis, FVB/NJ mouse model induces retinal degeneration. The cognitive impairment induced in their study was through ageing alone and the following consequences, while APP/PS1 mouse model acquired cognitive deficits through increased production and aggregation of human Ab peptides. In addition to ameliorating deficits associated with ageing and Ab, taurine proved to be effective with other forms of dementia: hypoxia-induced learning impairment, ischemic strokeinduced learning impairment, chemical-induced sporadic dementia of Alzheimer's type, and alcohol-induced brain impairment 14, 16, 19, 37, 38 . Consistent with our findings, taurine has been reported as ineffective to enhance spatial learning and memory in cognitively normal mice 20 . Accordingly, unlike acetylcholinesterase inhibitors, taurine seems to be dementia-specific, which may have great clinical impacts as a selective cognitive enhancer.
The results from our study indicate that taurine may play a role in preventing cognitive impairment in AD-like mouse model. However, the exact mechanism is not clear how taurine induces improvement of abnormal behaviours in AD model mice without the significant inhibition of Ab amyloidogenesis. The sandwich-ELISA results suggest that taurine weakly decreases Ab levels in the insoluble fraction of brain lysates but rarely alters concentrations of soluble Ab, including monomers and oligomers. In addition, histochemical analyses reveal that taurine does not affect b-sheet-rich plaques. As the current methods to isolate Ab in brain lysates into soluble, insoluble and guanidine-soluble fractions do not clearly define the contents, it is difficult to indicate specific alterations of monomers, oligomers, protofibrils and plaques. However, it is considerable that the levels of protofibrils with immature b-structures may be decreased by taurine treatment. Existence of protofibrils often provides confusing results in biochemical analyses measuring levels of high molecular weight Ab aggregates 39 . It is also unclear exactly how taurine interacts with Ab or by what mechanism it decreases the Ab level. There have been proposals regarding calcium and chloride modulation, but further studies are needed to reveal how taurine decreases Ab concentration in the brain. One hypothesis on how taurine can affect Ab levels is the direct interaction between taurine and Ab peptides in the brain. Previous studies on influences of taurine on amyloidogenesis have been controversial. Taurine in 1 mM slightly prevented Ab peptide comprising the residues 25-35 from polymerizing into fibrils 21 , suggesting a small inhibiting effect of taurine on Ab peptide aggregation. However, in the presence of 20 mM of taurine at pH of 5.5, Ab 40 peptides accelerated in aggregation but not at pH of 7.4 39 . Another hypothesis is that the sulfonic acid group in taurine may bind to Ab peptides and prevent glycosaminoglycans from binding to Ab, thereby inhibiting Ab aggregation 32, 40 . The structural similarity of homotaurine (tramiprosate), a former drug candidate, and taurine ( Figure 4) suggests that taurine may also interfere in glycosaminoglycans recruiting Ab 41 . We observed the increased expression of GFAP by taurine, in both wild-type and transgenic mice. Because many investigations reported reduced reactive astrocytes by taurine treatment, additional studies are warranted to determine correlation of taurine supplementation and GFAP alterations. Although such explorations may be beyond the scope of the current study, it is noteworthy that longterm administration of high-dose taurine (200 mg/kg/day, intraperitoneal) was also found to induce over expression of GFAP during improvement of the spatial learning and memory ability in SpragueDawley rats 15 . Our results suggest that taurine has a potential in treating deleterious effects on cognitive functions of AD. Taurine is already in clinical uses for congestive heart failure and liver disease with no known side-effects. Current prescription limits taurine supplementation to one year, but there is a dearth of adverse evidence for long-term taurine use. Previous studies assert that there are signs of beneficial effects in athletes 42 and in sleep-deprived students 43 . Moreover, the fact that taurine is effective via drinking water is a great convenience for the AD patients. Additional studies are warranted to determine whether these favorable actions of taurine will translate into a therapy that might potentially be useful in the early stage of AD.
Methods
Materials. DMSO, sodium carboxymethyl cellulose, taurine (median lethal dose: greater than 7,000 mg/kg), thioflavin S, glycine and sucrose were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). PBS was obtained from Gibco (Grand Island, New York, USA). 96-well plates (clear, black) were purchased from Corning (New York, New York, USA). Deionized water was generated by Milli-Q plus water system from Milliopore (Bedford, Massachusetts, USA).
Animals. Double APP/PS1 transgenic mice (strain name: B6C3-Tg (APPswe, PSEN1De9) 85Dbo/J) and wild type (B6C3F1) mice were obtained from Jackson Laboratory (Bar Harbor, Maine, USA). Both genes APP and PSEN1 were confirmed before the experiment began via a PCR instrument from Bio-Rad (S1000 ThermalCycler) using the standard PCR condition from Jackson Laboratory, the PCR-remix provided by Cosmo-Genetech (G-taq PCR premix kit, CMT-6002), and DNA from mice tails. The mice were 7 months of age at the beginning of the experiment, and they were housed in a room under controlled temperature, with an alternating 12 hrs lightdark cycle and access to food and water ad libitum. The behavioural tests were performed during the light period in a sound-attenuated and air-regulated experiment room. There was at least 30 min of habituation time before the behavioural tests began. All animal experiments were carried out in accordance with the National Institutes of Health guide for the care and use of laboratory animals (NIH Publications No. 8023, revised 1978). The animal studies were approved by the Institutional Animal Care and Use Committee of Korea Institute of Science and Technology.
Repeated oral dose studies. Taurine was orally administered via water at dose level of 0 (control) or 1,000 mg/kg/day for 6 weeks to 7-month old male APP/PS1 and wildtype mice: taurine-treated APP/PS1 (n 5 11), non-treated APP/PS1 (n 5 8), taurinetreated wild-type (n 5 10) and non-treated wild-type (n 5 10). We speculated that administering taurine orally via water should be effective since taurine can cross the blood-brain barrier, albeit in small amounts 44 . Amount of water intake per mouse was calculated by measuring the water consumption every day for each cage. Body weight of each animal was measured on the 0 th day and every 7 days afterwards. After the behavioural tests, the brains and CSF were collected under ether anesthesia. 19 Mice were perfused, and the other 20 mice had their cortices and hippocampi extracted.
Y-maze. The Y-maze test was performed after 6 weeks of oral taurine administration. The apparatus was a black, plastic maze with 3 arms (40 L 3 10 W 3 12 H cm) labeled A, B and C that converged to the middle, forming an equilateral triangle with 4 cm at its longest axis. Mice were placed at the end of one arm and allowed to move freely through the maze for 8 min, and the sequence of arm movements was manually recorded. When all 4 limbs of the mouse were within the pathway, it was considered an entry. An alternation was counted when a mouse successively entered 3 different arms. Spontaneous alternation behaviour was calculated based on the following equation:
% alternation~100 X number of alternations total arm entries{2
Passive avoidance. The passive avoidance test was performed 2 days after the Y-maze test. A 2-compartment shuttle chamber with a light compartment and a darker one containing a shock generator was used. For the acquisition trial, each mouse was first placed in a light chamber. After 10 sec, the door between the light/dark compartments was opened so that the mouse could move freely into the dark chamber. Upon entering the dark chamber, the door closed immediately and an electric foot shock (0.5 mA, 1 sec, once) was delivered through the floor grid. The mouse was then returned to its original cage for 24 hrs. For the retention trial after the 24 hrs, each mouse was placed into the light chamber, and the latency time between placement and entry into the dark chamber was measured (maximum 300 sec). Data was recorded and analyzed using a video camera-based Ethovision System (Nodulus, Netherlands). Data analyses including recordings of all behavioural responses were transcribed manually into the computer-acceptable format by keeping research colleagues blind.
Brain and CSF sample preparation. After the behavioural tests, mice were anesthetized with 2% avertin (20 mg/g, i.p.). Each group was divided approximately into half for perfusion and the other half for brain lysate. Brain lysates were developed by dissecting the hippocampal and cortical regions of mouse brains and homogenized using a lysis buffer (10 mM Tris-HCl, 5 mM EDTA in 320 mM sucrose, pH 7.4) containing 13 proteinase inhibitors cocktail for 30 min on ice 45 . The homogenates were centrifuged at 13,500 rpm, 4 uC for 30 min. Concentrations of cortical and hippocampal lysate supernatants were determined by Bradford protein assay. The perfusion began with 0.9% saline followed by ice cold 4% paraformaldehyde (pH 7. and mounted onto glass slides. CSF sampling was performed according to the method described previously 46 . Anesthetized mice were placed prone, and their cisterna magna were surgically exposed. The exposed meninges were penetrated with laboratory-produced capillary tube that had a tapered tip to obtain CSF. About 3-5 mL of CSF samples were obtained from each mouse.
Western blot. 20 mg of brain lysates were analyzed using a 10% SDS-gel electrophoresis. The proteins on the gel were transferred to a PVDF membrane. After the transfer, the membrane was blocked, then antibodies were employed. Immunoreactive bands were visualized using an enhanced chemiluminescence technique (Bio-Rad). The primary antibody information is the following: glial fibrillary acidic protein (GFAP, Millipore AB5541, 151,000) and actin as the loading control (Millipore MAB1501R, 1510,000). The secondary antibody information is the following: anti-mouse (Santa-Cruz, 1520,000) and anti-rabbit (Santa Cruz, 153,000).
ThS staining and immunohistochemistry. Ab plaque burden in cryo-sectioned brains were visualized using ThS staining. ThS was dissolved in 50% of ethanol at 500 mM and brain sections were stained for 7 min. Then, to remove non-specific binding of ThS dye, the sections were rinsed through 100, 95 and 90% of ethanol for 10 sec each and moved into PBS in succession. The brain sections were also stained for Ab and GFAP (Millipore AB5541). Ab was stained by monoclonal antibody (6E10). DAPI was also used for indication of the brain region. The images were taken on a Carl Zeiss LSM700 confocal microscope and a Leica DM2500 fluorescence microscope 47 . Data analyses including recordings of all behavioural responses were transcribed manually into the computer-acceptable format by keeping research colleagues blind. The mouse brain schematic diagrams in data were adapted from the Mouse Brain Atlas 48 .
Sandwich-ELISA. Sandwich-ELISA kit was purchased from Invitrogen, and the assays were performed on brain lysates and CSF following the manufacturer's directions and using the antibodies provided in the kit.
Statistics. Graphs were obtained with GraphPad Prism 5, and the statistical analyses were performed with one-way ANOVA followed by Bonferroni's post-hoc comparisons (*P , 0.05, **P , 0.01, ***P , 0.001, n.s.: no significance). The error bars represent the SEMs.
